Google unveils smartphone-based AI for diabetic retinopathy, heart valve disorders After Supreme Court win, Merck prevails against 500 Fosamax cases: report Cityblock Health names Toyin Ajayi CEO as startup eyes expansion into new markets From whiteboard to white coat: Roivant Social Ventures teams up with San Diego drug discovery center to bolster diversity in biopharma Hologic follows up year of European expansion with new innovation center in France Novartis' radiotherapy Pluvicto nabs FDA approval for prostate cancer, with $2B-plus peak sales expectations #FierceMadness: BMS' Zeposia, Gilead's Trodelvy and Lilly's Retevmo advance to Sweet 16 as Horizon's Tepezza wins big Most doctors have patients affected by social drivers but feel ill-equipped to address them, survey finds Pfizer grabs another breakthrough tag for RSV shot in older adults Sun Pharma forks over $485M to settle long-running legal battle inherited in Ranbaxy buyout Former J&J, BMS exec takes helm at COTA to drive use of real-world data in oncology, drug development Homology gets clarity on how to resolve pheNIX gene therapy hold Paige launches pathology AI for detecting breast cancer metastases in lymph nodes AstraZeneca's Imfinzi, chasing Merck's Keytruda in cervical cancer, flunks key trial Biogen sets up network to leverage real-world data for neurological disease drugs Featured Story | By Andrea Park At its second annual The Check Up event this week, Google Health introduced new research projects that would use artificial intelligence to turn smartphones into stethoscopes and other at-home disease screening tools. read more |
| |
|---|
|
Top Stories By Eric Sagonowsky For more than a decade, Merck has been defending itself against claims its osteoporosis drug Fosamax caused patients to suffer “atypical femoral fractures," even taking its fight to the Supreme Court, where it eked out a win. Now, after that SCOTUS fight, the company has prevailed against 500 Fosamax lawsuits. read more By Heather Landi Cityblock Health, a healthcare provider focused on marginalized populations with complex needs, has tapped Toyin Ajayi, M.D. as its new chief executive officer. read more By Max Bayer Roivant Social Ventures is partnering with San Diego-based drug discovery center Sanford Burnham Prebys to launch a new Ph.D. program designed to bolster diversity in biopharma. The program aims to provide hands-on training in all aspects of drug development, from discovery to clinical trials. read more By Andrea Park After spending much of 2021 growing its footprint beyond the U.S. by acquiring a handful of diagnostic developers scattered across Europe and expanding its women’s health-focused offerings throughout the continent, Hologic is deepening its ties there. read more By Angus Liu Novartis has pushed its second radioligand therapy over the FDA finish line. Building on the experience with Lutathera, the company hopes the new prostate cancer drug could reach over $2 billion in peak sales. read more By Ben Adams It’s March, so it’s time for some #FierceMadness. We’re looking for the best of the best in drug names—and this round we saw wins for Bristol Myers, BioMarin, Gilead, Eli Lilly and more, as AstraZeneca and Takeda drugs dropped out. Now it's time to get voting for your Elite 8. read more By Anastassia Gliadkovskaya Most physicians had at least some patients affected by social factors but felt inadequately equipped to address them. read more By Annalee Armstrong Pfizer’s respiratory syncytial virus (RSV) program is piling on the wins. After gaining a breakthrough tag for its maternal vax program earlier this month, the New York pharma added the same designation for prevention of RSV in older adults. read more By Zoey Becker The good news for Sun Pharma is that it's closed the books on one more legal problem it inherited from its Ranbaxy Laboratories buyout eight years ago. The bad: It's going to cost the generics maker $485 million. read more By Heather Landi As COTA looks to expand its oncology real-world data and analytics expertise in healthcare and life sciences, the company tapped pharma veteran Miruna Sasu, Ph.D., as its new CEO and president. read more By Annalee Armstrong Homology Medicines is adding an immunosuppressive regimen to a phase 1/2 trial for its phenylketonuria gene therapy, hoping to quell FDA concerns that triggered a clinical hold in February. read more By Conor Hale Paige’s AI program aims to increase the chances of spotting potential tumors of any size, including micrometastases that might otherwise go unnoticed. read more By Kevin Dunleavy The roller coaster ride for AstraZeneca’s blockbuster cancer drug Imfinzi has taken a sudden dip, with a swing and a miss in cervical cancer. The company said its phase 3 trial of Imfinzi combined with chemoradiotherapy failed to show that it could slow disease progression and extend the chance for survival better than chemoradiotherapy alone. read more By Gareth Macdonald Aduhelm maker Biogen has set up a data network to track how neurological disease medicines perform in the real world after clinical trials. read more |
